Indications |
Oral Epilepsy Adult: Initially, 300 mg on the 1st day, 300 mg bid on the 2nd day and 300 mg tid on the 3rd day. Thereafter, may increase dose until effective antiepileptic control is achieved. Usual maintenance range: 0.9-3.6 g daily; daily dose to be taken in 3 equally divided doses and max dosing interval: 12 hr. Max: 4.8 g daily. Child: 6-12 yr: Initially, 10 mg/kg on the 1st day, 20 mg/kg on the 2nd day and 25-35 mg/kg on the 3rd day. Maintenance: 1200 mg daily (37-50 kg); 900 mg daily (26-36 kg). Total daily dose to be taken in 3 equally divided doses. Renal impairment: Total daily doses to be taken as 3 divided doses. Haemodialysis: Loading dose: 300-400 mg followed by 200-300 mg after each 4 hr of haemodialysis.
Oral Neuropathic pain Adult: Titrate to a max of 1.8 g daily in 3 divided doses. Renal impairment: Total daily doses to be taken as 3 divided doses. Haemodialysis: Loading dose: 300-400 mg followed by 200-300 mg after each 4 hr of haemodialysis.
Special Populations: Renal impairment: CrCl: 50-79 mL/min: 600-1200 mg daily; 30-49 mL/min: 300-600 mg daily; 15-29 mL/min: 150 mg daily (or 300 mg every other day) to 300 mg daily; <15 mL/min: 150 mg daily (or 300 mg every other day). To be given in 3 divided doses. Recommended loading dose for patients undergoing haemodialysis who have never received gabapentin: 300-400 mg, followed by 200-300 mg after each 4 hr of haemodialysis. |
||||||||||||||||||||
Contraindications |
Hypersensitivity. Lactation. | ||||||||||||||||||||
Warnings / Precautions |
Discontinuation or transfer from other antiepileptics, history of psychotic illness; renal impairment; pregnancy. Gradual withdrawal over at least 7 days to prevent an increase in seizure frequency. | ||||||||||||||||||||
Adverse Reactions |
Somnolence, dizziness, ataxia, weakness, paraesthesia, fatigue, headache; nystagmus, diplopia; nausea, vomiting, wt gain, dyspepsia; rhinitis; tremor; leucopenia; altered LFTs; Stevens-Johnson syndrome. | ||||||||||||||||||||
Drug Interactions |
Cimetidine may reduce gabapentin clearance. Absorption reduced with antacids. See Below for More gabapentin Drug Interactions |
||||||||||||||||||||
Lab Interactions |
False-positive readings with some urinary protein tests. | ||||||||||||||||||||
Mechanism of Actions |
Gabapentin is structurally related to the neurotransmitter GABA but is neither a GABA agonist nor antagonist. Gabapentin-binding sites have been identified throughout the brain tissues e.g. neocortex and hippocampus. However, the exact mechanism of action is still unknown. Absorption: 50-60% absorbed (oral); peak plasma concentrations after 2 hr. Distribution: Widely distributed; enters breast milk. Protein-binding: Minimal. Metabolism: Poor. Excretion: Urine and faeces; 5-7 hr (elimination half-life). |
||||||||||||||||||||
Administration |
May be taken with or without food. |
||||||||||||||||||||
Storage Conditions |
Oral: Store at 20-25°C. Oral solution: Refrigerate at 2-8°C. | ||||||||||||||||||||
ATC Classification |
N03AX12 - gabapentin ; Belongs to the class of other antiepileptics. | ||||||||||||||||||||
Storage |
Oral: Store at 20-25°C. Oral solution: Refrigerate at 2-8°C. | ||||||||||||||||||||
Available As |
|
Gabapentin
Post Review about Gabapentin Click here to cancel reply.
Gabapentin Containing Brands
Gabapentin is used in following diseases
Drug - Drug Interactions of Gabapentin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.